Clinical trial · no report yet · Phase 2
RIBOLARIS
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
- NCT05296746 ↗
- Active, not recruiting
- SOLTI Breast Cancer Research Group
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 15 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Breast Cancer Stage II
- Interventions
- Ribociclib (neoadjuvant); Chemotherapy (adjuvant); Ribociclib (adjuvant)
- Arms
- Responder (ROR-low) · Experimental
- Non-responder (ROR-medium/high) · Other
- Enrollment
- 1,100 (estimated)
- Primary outcomes
- Distant metastasis-free survival (DMFS) in the ROR-low cohort (responder cohort)
- Sponsor
- SOLTI Breast Cancer Research Group with Novartis, UNICANCER
- Start
- May 3, 2022
- Primary completion
- Oct 1, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05296746 · updated May 14, 2026
Publications
linked from the registry- Cottu P, Pascual T, Lemonnier J, Hu H, Roux E, Connolly RM, Ma CX, Wolff AC, Crestani T, Tolosa P, Ferrero-Cafiero JM, Mulero-Sanchez A, Salvador F, Villacampa G, Gavila J, de La Motte Rouge T, Prat A. Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer. Ther Adv Med Oncol. 2026 Aug 13;18:17588359261467380. doi: 10.1177/17588359261467380. eCollection 2026. PubMed 42602220